Japan spinal cord


Medical infomationMedical infomation

2012 Research information


Accomplishment report session 2011: MEXT*1 " Life science Coordination, Support and Training Program for Translational Research"
Program secretariat: Foundation for Biomedical Research and Inovation
*1;Ministry of Education, Culture, Sports, Science and Technology
〇Keynote lecture Mari Dezawa*2”Possibility of the regeneration medicine by a new multipotential Muse cell*3”
*2;Dept. of Stem Cell Biology and Histology,Tohoku University Graduate School of Medicine.
【original paper】
*3;Muse=Multiliniage-differentiating stress enduring cell

【Poster exhibition】
〇Dept. of Neurosurgery, Osaka University
Autogenous OEC (olfactory ensheathing cells)transplantation to chronic SCI patient(ASIA-A)
Four persons' treatment results : thigh can be crooked(2), leg can be lengthened(1), crutch walking by a brace is possible(2)
This treatment approach was specified as "advanced medicine"(SENSHIN IRYO*) in December, 2012.
* Some medical expenses become adaptation of a medical insurance.

〇Yoshihisa Suzuki (department of plastic surgery Kitano Hospital, Kyoto)
Autogenous MSC (mesenchymal stem cell ) transplantation to an acute SCI patient. End of a clinical trial :Sept. 2009.
Joint research with Kyoto University and Kansai Medical University.
Four persons' treatment results(phaseⅠ)
case1・4・5:ASIA-A→A, case2: B→D, case3:C→D
* Applied for the clinical trial (Phase I/II) of myelomonocytic cell transplan tation to SCI patient to the MHLW in June, 2011.


iPS Cell:Hope for hereditary disease medical treatment-- natural restoration cell is chosen.
【original paper】 Cheng, L.T., Tada,T* et al.. (2012) “Cure of ADPKD by selection for spontaneous genetic repair events in Pkd1-mutated iPS cells”. PLoS ONE, 7, e32018.

Takashi Tada: Stem Cell Engineering, Stem Cell Research Center, Institute for Frontier Medical Sciences, Kyoto University

Feb. 2

MHLW(Ministry of Health, Labour and Welfare):“Guidelines on clinical research using human stem cells”【Revised edition】English version(PDF)

Jan. 5

Pr. Shiya Yamanaka(CiRA, Kyoto University) interview: “The first target this year is a iPS cell bank!” report of Sankei Shinbun (Japanese)

2011 Research information


Minoru Ueda* et al. ”Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuro- regenerative mechanisms” Journal of Clinical Investigation , 122-1;80-90, 2012
Graduate School of Medicine Program in Cellular Information Medicine, Nagoya University

Nov. 19

46th Annual Meeting of Japan Medical Society of Spinal Cord Lesion
Symposium: Regenerative medicine in spinal cord injury―present and view.

〇 Toru Ogata*1“Novel blood biomarkers for evaluating severity of spinal cord injury
*1: Department of Rehabilitation for the Movement Functions, Research Institute National Rehabilitation Center for Persons with Disabilities
〇 Seiji Okada*2“In situ analysis for engrafted neural stem/progenitor cells in injured spinal cord”
*2: Department of Advanced Medical Initiatives, Faculty of Medical Sciences, Kyusyu University/Orthopaedic surgery 〇 Naosuke Kamei, Mitsuo Ochi*3 et al. ”Neovascularization therapy for the spinal cord injury”
*3: Dep. of Orthopaedic surgery, Hiroshima University
〇 Satoshi Nori, Hideyuki Okano*4 et al. ”Transplantation of human neural stem/progenitor cells for the treatments of spinal cord injury”
【original paper】PNAS 108;16825-16830,2011
*4: Nori/ orthopaedic surgery, Okano/Physiology, Keio University
Okano lab.
Okano lab. SCI group
〇Masashi Yamazaki, Masao Koda*5 et al. ”Clinical trial of neuroprotective therapy using G-CSF for patients with acute spinal cord injury and acute progressive compression myelopathy”
【related paper】
Koda M, Nishio Y, Kamada T, et al., 2007. Brain Res, 1149:223-231.
Nishio Y, Koda M, Kamada T, et al., 2007. J Neuropathol Exp Neurol 66:724-731.
*5: Dep. of Orthopaedic surgery, Chiba University

Nov. 19

Symposium: Front line of regenerative medicine research hosted byMEXT iPS cell research network
MEXT; Ministry of Education, Culture, Sports, Science and Technology
〇Masayo Takahasi* “Clinical traial of the retinitis pigmentosa by an iPS cell will be started in 2013”
Retinal Regeneration, RIKEN CDB(Center for Developmental Biology)
【related paper】Jin Z. B, et al. Modeling retinal degeneration using patient-specific induced pluripotent stem cells. PLoS One 6.e17084 (2011)

Oct. 4

Satoshi Nori, Hideyuki Okano*”Grafted human-induced pluripotent stem- cell-derived
neurospheres promote motor functional recovery after spinal cord injury in mice.” PNAS (Proc Natl Acad Sci U S A.) 108;16825-16830,2011
*: Nori/ orthopaedic surgery, Okano/Physiology, Keio University

Sept. 16

Neuroscuence 2011 (Japan Neuroscience Society) Special program of the patient groups: From “neuroscience research” to “therapeutic drug”;20-years effort before HGF has become medicine.
〇 Masashi Aoki*“Clinical trial of HGF to ALS” (scheduled for 2012)
〔relevant material〕
Kringle Initiates Phase 1 Clinical Trial of Recombinant Human HGF for the Treatment of Incurable Neuronal Diseases.
* Dept. of neurology, Tohoku University
〇 Hideyuki Okano“Clinical trial of HGF to SCI” (after several years)*Dept. of Physiology, Keio University
Japan Spinal Cord Foundation
Japan ALS Association

Mar. 1

damaged optic nerve is reproduced with a mouse.
【original paper】Fujita, Y., Endo, S., Takai, T. and Yamashita, T*. (2011) “Myelin suppresses axon regeneration by PIR-B/SHP-mediated inhibition of Trk activity”. EMBO J. 30, 1389-1401.
Department of Molecular Neuroscience, Osaka University

Mar. 2

Japanese Society for Regenerative Medicine